Panamesine | 139225-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Panamesine
• 英文别名: (5S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxypiperidin-1-yl]methyl]-3-(4-methoxyphenyl)-1,3-oxazolidin-2-one
• CAS: 139225-22-2
• 化学式: C₂₃H₂₆N₂O₆
• 分子量: 426.5
• InChiKey: NINYZUDVKTUKIA-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] METHODS OF TREATMENT FOR CANCER, STEROL HOMEOSTASIS, AND NEUROLOGICAL DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER, D'HOMÉOSTASIE DES STÉROLS ET DE MALADIES NEUROLOGIQUES
  申请人：UNIV TEXAS

  公开号：WO2018156883A1

  公开（公告）日：2018-08-30

  The present disclosure provides methods of treating cancer, sterol homeostasis diseases, and neurological diseases using compounds which modulate the activity of sigma receptors. In particular, the present disclosure provides method s of modulating the sigma 2 receptor for use in treating one or more diseases associated with that sigma receptor.

  本公开提供了一种利用调节西格玛受体活性的化合物治疗癌症、甾醇稳态疾病和神经系统疾病的方法。具体而言，本公开提供了一种调节西格玛2受体的方法，用于治疗与该西格玛受体相关的一个或多个疾病。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF
  申请人：Rogers Robin D.

  公开号：US20120046244A1

  公开（公告）日：2012-02-23

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.

  本文揭示了包括活性药物、生物和营养化合物的离子液体组成，以及使用方法。进一步揭示了液态离子对或其溶液的物质组成和使用方法；包括“溶剂化”的离子液体组成，例如“水化”的离子液体组成及其用途。